Akari Therapeutics, Plc
Price Action
Technical Summary
CONSOLIDATINGAkari Therapeutics, Plc is in a consolidation phase, trading with mixed signals as moving averages converge. Relative strength is leading (RS Rating: 80), indicating clear outperformance against the broad market. Earnings contraction of 153% provides fundamental context to the price action. Investors should exercise caution due to high volatility (170% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $12.98 | -25.32% | BELOW |
| 50 SMA | $9.55 | +1.47% | ABOVE |
| 100 SMA | $8.59 | +12.81% | ABOVE |
| 150 SMA | $9.87 | -1.85% | BELOW |
| 200 SMA | $15.37 | -36.95% | BELOW |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is AKTX in an uptrend right now?
AKTX has a trend score of 2/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 2 of 4 trend criteria are met.
Is AKTX overbought or oversold?
AKTX's RSI (14) is 47. The stock is in neutral territory, neither overbought nor oversold.
Is AKTX outperforming the market?
AKTX has a Relative Strength (RS) Rating of 80 out of 99. Yes, AKTX is a market leader, outperforming 80% of all stocks over the past 12 months.
Where is AKTX in its 52-week range?
AKTX is trading at $9.69, which is 20% of its 52-week high ($49.60) and 19% above its 52-week low ($0.25).
How volatile is AKTX?
AKTX has a Beta of 1.79 and 52-week volatility of 170%. It's more volatile than the S&P 500 - expect bigger swings.